Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

DLL3 Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (2) CD3 (2) CD47 (1) Notch (5)
By Research Areas:	Cancer (7) Inflammation/Immunology (7)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990104

*Anti-DLL3* Antibody (anti-DLL3 arm derived from AMG-757)**	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99043

Rovalpituzumab 1 Publications Verification	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P990896

FZ-A038	ADC Antibody	Cancer
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .

HY-164729

FZ-AD005	Antibody-Drug Conjugates (ADCs)	Cancer
FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer .

HY-P990920

Gocatamig MK-6070; HPN328	CD3	Inflammation/Immunology
HY-P990920 is an *CD3E/ALB/DLL3*-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .

HY-132257

Rovalpituzumab tesirine SC-002	Antibody-Drug Conjugates (ADCs) Notch	Cancer
Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer effects. Rovalpituzumab tesirine contains a DLL3-targeting antibody Rovalpituzumab (HY-P99043) tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. Rovalpituzumab tesirine can be used for the stduy of small cell lung cancer (SCLC) .

HY-P991016

Peluntamig PT-217	CD47	Inflammation/Immunology
HY-P991016 is an *CD47/DLL3*-targeting H-γ1_L-κ type bispecific antibody .

HY-P991173

AMG-119	Notch	Cancer
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990932

Obrixtamig BI 764532; OBT 620	CD3	Inflammation/Immunology
HY-P990932 is an *CD3E/DLL3*-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .

Cat. No.	Product Name	Target	Research Area

HY-P990401

Anti-DLL3 Antibody	Inhibitory Antibodies	Inflammation/Immunology
The Anti-DLL3 Antibody is a humanized antibody expressed in CHO, targeting *DLL3. The predicted molecular weight (MW) of the Anti-DLL3* Antibody is 146.36 kDa. The isotype control for the Anti-DLL3 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990104

*Anti-DLL3* Antibody (anti-DLL3 arm derived from AMG-757)**	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99043

Rovalpituzumab 1 Publications Verification	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P99575

Tarlatamab AMG-757	Notch	Inflammation/Immunology Cancer
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the K_Ds of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the K_Ds of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .

HY-P990896

FZ-A038	ADC Antibody	Cancer
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .

HY-P990920

Gocatamig MK-6070; HPN328	CD3	Inflammation/Immunology
HY-P990920 is an *CD3E/ALB/DLL3*-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .

HY-P991016

Peluntamig PT-217	CD47	Inflammation/Immunology
HY-P991016 is an *CD47/DLL3*-targeting H-γ1_L-κ type bispecific antibody .

HY-P990981

Clesitamig	Inhibitory Antibodies	Inflammation/Immunology
HY-P990981 is an *DLL3*-targeting (V-κ-G4CH1-G1h-H-γ1_L-κ)_Lκ)]_(H-γ1_L-κ) type humanized antibody .

HY-P991173

AMG-119	Notch	Cancer
AMG-119 is a humanized IgG1 monoclonal antibody that targets delta-like ligand 3 (DLL3). AMG-119 can be used for the study of relapsed/refractory (R/R) small cell lung cancer (SCLC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990932

Obrixtamig BI 764532; OBT 620	CD3	Inflammation/Immunology
HY-P990932 is an *CD3E/DLL3*-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83770

	DLL3 Antibody(YA3566) SCDO1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat
	DLL3 Antibody(YA3566) is a mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to DLL3. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human, rat.

HY-P84837

	DLL3 Antibody (YA4534) SCDO1	WB, IHC-P, ICC/IF, FC, ELISA	Human, Rat
	DLL3 Antibody (YA4534) is a mouse-derived and non-conjugated IgG2a antibody, targeting to DLL3. It can be applicated for WB, IHC-P, ICC/IF, FC, ELISA assays, in the background of human, rat.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.